Pamapimod-d4

Pamapimod-d4 is a deuterated form of Pamapimod, which is a potent and highly selective inhibitor of p38α mitogen-activated protein kinase (MAPK). The chemical structure of Pamapimod-d4 contains four deuterium atoms that replace four hydrogen atoms in Pamapimod, which gives it greater stability and improved pharmacokinetic properties. Pamapimod-d4 is primarily used in preclinical research to study the role of p38α MAPK in various diseases, including autoimmune disorders, inflammatory diseases, and cancer. The inhibition of p38α MAPK by Pamapimod-d4 has been shown to reduce the production of pro-inflammatory cytokines and chemokines, which are involved in the pathogenesis of many inflammatory diseases. This has led to the development of Pamapimod-d4 as a potential therapeutic agent for the treatment of rheumatoid arthritis, psoriasis, and other inflammatory conditions. In terms of chemical information, Pamapimod-d4 has a molecular weight of 424.56 g/mol and a chemical formula of C19H18D4N5O2S. It has a melting point of 204-206 °C and is soluble in dimethyl sulfoxide (DMSO), ethanol, and methanol. Pamapimod-d4 is stable under normal conditions and has a half-life of approximately 6 hours in vivo. In conclusion, Pamapimod-d4 is a valuable tool in preclinical research for studying the role of p38α MAPK in inflammatory diseases and other conditions. Its stable and improved pharmacokinetic properties make it a promising candidate for further development as a therapeutic agent.